市場調查報告書
商品編碼
1087059
黑色素瘤治療:市場預測(2022年~2027年)Melanoma Treatment Market - Forecasts from 2022 to 2027 |
全球黑色素瘤治療的市場規模預測將從2020年的35億8,600萬美金,在預測期間內預計將以15.12%的年複合成長率擴大,到2027年達到96億800萬美元。
本報告提供黑色素瘤治療的世界市場調查,提供市場規模和預測,市場促進因素及課題,市場趨勢,各市場區隔的市場分析,競爭情形,主要企業的簡介等系統性資訊。
The melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period to reach a market size of US$9.608 billion by 2027, increasing from US$3.586 billion in 2020.
Introduction.
In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.
Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining the market share due to lesser side effects and high efficiency rates.
Growth Factors.
The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has made the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were some of the approved drugs for the treatment by FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.
Impact of COVID-19 on the Melanoma Treatment Market
The pandemic has had a lagging effect on various diagnostic methods due to several restrictions and risk exposure of the comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which disproportionately affected the elderly, females, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.
Competitive Insights.
The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.
Segmentation:
Cutaneous Melanoma
Ocular Melanoma
Mucosal Melanoma
Surgery
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy
North America
South America
Europe
Middle East and Africa
Asia Pacific